Daily non-political popular news in brief.
HGS announces results of Phase 2B trial of Albuferon for chronic hepatitis C
11-05-2007 · EurekAlert!This Phase 2b study demonstrated that, with half as many injections as Pegasys (peginterferon alfa 2a), Albuferon was just as effective in achieving sustained virologic response -- an undetectable amount of virus in the blood at 24 weeks following the end of treatment -- with comparable safety and less impairment of health-related quality of life on treatment. Albuferon is administered every two weeks, while peginterferon alfa-2a requires administration every week.
Read more »
Keywords: hgs, announces, results, phase, trial, albuferon, chronic, hepatitis, announce, result, hepatiti
« Previous | Next »
Similar news on "HGS announces results of Phase 2B trial of Albuferon for chronic hepatitis C":
- HGS unveils positive QOL results from Phase 2B trial of Albuferon for hepatits C
11-05-2007 · EurekAlert!
The study demonstrated that patients in the Albuferon treatment groups reported fewer missed days of work and less impairment of health-related quality of life on treatment compared to the Pegasys (peginterferon alfa-2a) group.
Similar news · Read more »
- Acrux announces positive clinical trial resultswith combination contraceptive sprays
07-03-2007 · EurekAlert!
Acrux, the Australian drug delivery company, today announced positive results from its Phase 1 clinical studies using two unique contraceptive skin sprays, each containing a progestin and an estrogen.
Similar news · Read more »
- Drug-based on MGH discovery may significantly improve treatment of dangerous blood disorder
01-31-2008 · EurekAlert!
Two clinical trials of the novel drug romiplostim show that it significantly improved platelet levels in patients with chronic immune thrombocytopenic purpura, a hematologic disorder that can cause uncontrolled bleeding. An international research team reports Phase 3 trial results for the drug, which duplicates the action of a natural hormone discovered by a Massachusetts General Hospital investigator, in the Feb. 2 issue of The Lancet.
Similar news · Read more »
- Shire announces once-daily guanfacine extended release data in ADHD patients aged 6 to 17 years
11-16-2006 · EurekAlert!
Shire plc (Nasdaq: SHPGY, LSE: SHP, TSX: SHQ) announced that once-daily doses of the investigational medication guanfacine extended release (GXR, also referred to as SPD503), a selective alpha-2A-adrenoceptor agonist, significantly improved symptoms of Attention-Deficit/Hyperactivity Disorder in children aged 6 to 17 years when used as a monotherapy, according to phase 3 trial results presented at the 2006 US Psychiatric & Mental Health Congress. Two additional studies also released at the meeting report the pharmacokinetic profile of GXR.
Similar news · Read more »
- Drug based on MGH discovery may significantly improve treatment of dangerous blood disorder
01-31-2008 · EurekAlert!
Two clinical trials of the novel drug romiplostim show that it significantly improved platelet levels in patients with chronic immune thrombocytopenic purpura, a hematologic disorder that can cause uncontrolled bleeding. An international research team reports Phase 3 trial results for the drug, which duplicates the action of a natural hormone discovered by a Massachusetts General Hospital investigator, in the Feb. 2 issue of the Lancet.
Similar news · Read more »
- SinuNase Phase 3 show almost 100 percent of chronic sinusitis cases are from fungal-induced inflamma
09-10-2007 · EurekAlert!
Accentia Biopharmaceuticals announces evidence that most, if not all cases of chronic sinusitis, are due to a fungal-induced inflammation as originally proposed by investigators at the Mayo Clinic. The data were collected as part of the company's ongoing pivotal phase 3 clinical trial for its lead pharmaceutical product, SinuNase™, an intranasal formulation of the antifungal amphotericin B 0.01 percent suspension.
Similar news · Read more »
- Phase I study of novel gene therapy for HIV
11-06-2006 · EurekAlert!
The results are in for Phase I clinical trials of a gene therapy for AIDS. The trial was conducted at U-Penn where five patients with chronic HIV who had failed prior therapies were given a one-time infusion. They all tolerated the therapy and showed improved immune system response. This is the first publication of an effective gene therapy for AIDS to show positive clinical results in the peer review literature.
Similar news · Read more »
- HGS announces positive Phase 2 LymphoStat-B at ACR meeting
11-09-2007 · EurekAlert!
Human Genome Sciences, Inc. today announced the presentation of Phase 2 clinical results demonstrating that LymphoStat-B (belimumab) achieved a sustained improvement in disease activity across multiple clinical measures, decreased the frequency of disease flares over time, and was well tolerated through 2.5 years on treatment in combination with standard of care in patients with active systemic lupus erythematosus.
Similar news · Read more »
- Accentia issues update on blinded results in phase 3 of SinuNase for chronic sinusitis
08-15-2007 · EurekAlert!
Based on an interim blinded analysis of the first group of the more than 80 patients who have now completed the trial at 16 weeks, the study has shown improvement in polyposis by endoscopy in about 50 percent of patients (N=43) and improvement in sinus inflammation by CT scan in approximately 50 percent of patients (N=23). Moreover, 50 percent of patients with objective evidence of improvement have achieved the primary endpoint of complete resolution of cardinal symptoms.
Similar news · Read more »
- GSK announces launch of largest ever Phase III trial in lung cancer treatment
06-05-2007 · EurekAlert!
GlaxoSmithKline today announced final results of a Phase II clinical trial of its investigational Antigen-Specific Cancer Immunotherapeutic MAGE-A3 in non small cell lung cancer. Final trial analysis showed a 27 percent reduction in the relative risk of cancer recurrence following surgery, compared to placebo. GSK also announced today the launch of a Phase III efficacy and safety trial for this novel cancer immunotherapy; the largest clinical trial ever conducted in lung cancer treatment.
Similar news · Read more »
